ArticleJournal of immunotherapy (Hagerstown, Md. : 1997)2012
The role of antigen cross-presentation from leukemia blasts on immunity to the leukemia-associated antigen PR1.
Article in Journal of immunotherapy (Hagerstown, Md. : 1997), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 29 citations in OpenAlex.
- Article
- Hu8F4-CAR T cells with mutated Fc spacer segment improve target specificity and mediate anti-leukemia activity in vivo.Cytotherapy · 2024Article
- Hu8F4-CAR T cells with mutated Fc spacer segment improve target-specificity and mediate anti-leukemia activityResearch square · 2024Article
- Autoimmune HLA Alleles and Neoepitope Presentation Predict Post-Allogenic Transplant Relapse.Journal of immunotherapy and precision oncology · 2023Article
- Membrane-Associated Proteinase 3 on Granulocytes and Acute Myeloid Leukemia Inhibits T Cell Proliferation.Journal of immunology (Baltimore, Md. : 1950) · 2018Article
- A Novel T-Cell Engaging Bi-specific Antibody Targeting the Leukemia Antigen PR1/HLA-A2.Frontiers in immunology · 2018Article
- Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells.Cancer research · 2017Article
- Neuropilin-1 mediates neutrophil elastase uptake and cross-presentation in breast cancer cells.The Journal of biological chemistry · 2017Article
- Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells.Cancer immunology research · 2017Article
- Cathepsin G Is Expressed by Acute Lymphoblastic Leukemia and Is a Potential Immunotherapeutic Target.Frontiers in immunology · 2017Article
- Functional exhaustion of CD4Immunology · 2016Article
- Autophagy and proteasome interconnect to coordinate cross-presentation through MHC class I pathway in B cells.Immunology and cell biology · 2016Article
- Neutrophil elastase enhances antigen presentation by upregulating human leukocyte antigen class I expression on tumor cells.Cancer immunology, immunotherapy : CII · 2016Article
- Cross-platform comparison of independent datasets identifies an immune signature associated with improved survival in metastatic melanoma.Oncotarget · 2016Article
- Dendritic cell-based immunotherapy for myeloid leukemias.Frontiers in immunology · 2013Review
- Targeting cathepsin G in myeloid leukemia.Oncoimmunology · 2013Article
- A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Article
- Broad cross-presentation of the hematopoietically derived PR1 antigen on solid tumors leads to susceptibility to PR1-targeted immunotherapy.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- Article
- HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance.OncoimmunologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 5 institutions in 2 countries.
Funding
Abstract
Cross-presentation is an important mechanism by which exogenous tumor antigens are presented to elicit immunity. Because neutrophil elastase (NE) and proteinase-3 (P3) expression is increased in myeloid leukemia, we investigated whether NE and P3 are cross-presented by dendritic cells (DC) and B cells, and whether the NE and P3 source determines immune outcomes. We show that NE and P3 are elevated in leukemia patient serum and that levels correlate with remission status. We demonstrate cellular uptake of NE and P3 into lysosomes, ubiquitination, and proteasome processing for cross-presentation. Using anti-PR1/human leukocyte antigen-A2 monoclonal antibody, we provide direct evidence that B-cells cross-present soluble and leukemia-associated NE and P3, whereas DCs cross-present only leukemia-associated NE and P3. Cross-presentation occurred at early time points but was not associated with DC or B-cell activation, suggesting that NE and P3 cross-presentation may favor tolerance. Furthermore, we show aberrant subcellular localization of NE and P3 in leukemia blasts to compartments that share common elements of the classic major histocompatibility class I antigen-presenting pathway, which may facilitate cross-presentation. Our data demonstrate distinct mechanisms for cross-presentation of soluble and cell-associated NE and P3, which may be valuable in understanding immunity to PR1 in leukemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.